Journal of Medical Academics

Register      Login

VOLUME 2 , ISSUE 2 ( July-December, 2019 ) > List of Articles

Original Article

Socioepidemiological Determinants of Human Immunodeficiency Virus associated Tuberculosis Coinfection in Northern India: A 1:2 Matched Case Control Study

Rakesh Khajuria, Sumeena Bajaj, Jugal Kishore, Divyansh Bajaj

Keywords : Human immunodeficiency virus, Human immunodeficiency virus infection-associated tuberculosis coinfection, people living with HIV-AIDS, Tuberculosis,Antiretroviral therapy

Citation Information : Khajuria R, Bajaj S, Kishore J, Bajaj D. Socioepidemiological Determinants of Human Immunodeficiency Virus associated Tuberculosis Coinfection in Northern India: A 1:2 Matched Case Control Study. Journal of Medical Academics 2019; 2 (2):48-53.

DOI: 10.5005/jp-journals-10070-0036

License: CC BY-NC 4.0

Published Online: 00-12-2019

Copyright Statement:  Copyright © 2019; Jaypee Brothers Medical Publishers (P) Ltd.


Abstract

Aims: Our study was designed to assess the sociodemographic correlates of human immunodeficiency virus infection-associated tuberculosis (HIV-TB) coinfection and elucidate its risk factors among patients attending a tertiary healthcare facility in Northern India. Materials and methods: A 1:2 case–control study, wherein the case group (patients with HIV-TB) was compared with two control groups: I group comprising patients with active tuberculosis (TB) [but without human immunodeficiency virus (HIV)] and II group comprising HIV patients (who did not develop active TB during follow-up). Our questionnaire was designed to obtain data based on sociodemographic and detailed medical history. Results: Significant differences were observed on comparing gender, age, educational level, per capita income, place of residence, and occupational profile between case group and control group I. Case group was more likely to reside in urban areas (p = 0.001) and had a lower average level of formal education (p = 0.009) as compared to control group II. Conclusion: We found patients in the coinfected group to differ significantly from patients with active TB alone, but the trends were similar to the control group I. The most frequent high-risk behavior was observed to be unprotected sexual activity, which is in concordance with the national estimates by National AIDS Control Organization (NACO) and World Health Organization (WHO). Clinical significance: To minimize the prevalence of HIV-TB, controlling HIV transmission and disease progression in people living with HIV-AIDS (PLHAs) is crucial. Moreover, if the life expectancy of PLHAs is to be improved, HIV should be diagnosed early in the natural history of infection.


PDF Share
  1. Kendrad N, Carolyn W, Neil G. Infectious diseases epidemiology, theory and practice. Aspen publishers; 2001. pp. 411, 428, 521.
  2. WHO. Global Tuberculosis Report 2016. Geneva: World Health Organization. (homepage on internet).c2014.(updated 31 Mar 2016, cited 30 Nov 2016). Available at www.who.int/tb/publications/global_report/gtbr14_executive_summary.pdf (last Assessed on 25 June 2016).
  3. Corbett EL, Watt CJ, Walker N. The growing burden of tuberculosis: Global trends and interactions with the HIV epidemic. Arch Intern Med 2003;163(9):1009–1021. DOI: 10.1001/archinte.163.9.1009.
  4. Narrative country progress report of India: Global AIDS Response Progress Reporting 2015. NACO.GOI/NACO/SIM/GR-RPT/200415. Available from: http://www.unaids.org/sites/default/files/country/documents/IND_narrative_report_2015.pdf, (last assessed on 25 June 2016).
  5. Agarwal U, Kumar A, Behera D. Profile of HIV associated tuberculosis at a tertiary institute in setting of free anti-retroviral therapy. JAPI 2009;57:685.
  6. Sculier D, Getahun H, Granich R, et al. Priority research questions for TB/HIV in HIV-prevalent and resource-limited settings. Geneva: World Health Organization; 2010.
  7. World Health Organization. Guidelines for intensified tuberculosis case-finding and isoniazid preventive therapy for people living with HIV in resource constrained settings; 2011 [cited 2014 Nov 13]. Available from: http://whqlibdoc.who.int/publications/2011/9789241500708_eng.pdf.
  8. Vikram A. HIV and tuberculosis: a “cursed duo” in the HAART era. J Assoc Physicians India 2009;57:681–682.
  9. Getahun H, Gunneberg C, Granich R, et al. HIV infection-associated tuberculosis: the epidemiology and the response. Clin Infect Dis 2010;50(Suppl 3):S201–S207. DOI: 10.1086/651492.
  10. Fenner L, Forster M, Boulle A, et al. Tuberculosis in HIV programmes in lower-income countries: practices and risk factors. Int J Tuberc Lung Dis 2011;15(5):620–627. DOI: 10.5588/ijtld.10.0249.
  11. Hwang JH, Choe PG, Kim NH, et al. Incidence and risk factors of tuberculosis in patients with human immunodeficiency virus infection. J Korean Med Sci 2013;28(3):374–377. DOI: 10.3346/jkms.2013.28.3.374.
  12. Sharma SK, Mohan A, Tamilarasu K. HIV-TB coinfection: epidemiology, diagnosis & management. Indian J Med Res 2005;121(4):550–567.
  13. Londhey VA. HIV and tuberculosis – A “cursed duo” in the HAART Era. [Last accessed on Feb 14, 2017]. Available from: http://www.japi.org/october_2009/article_01.pdf.
  14. Narain JP, Lo YR. Epidemiology of HIV-TB in Asia. Indian J Med Res 2004;120(4):277–289.
  15. WHO. Global Tuberculosis Report 2015. Geneva, World Health Organization. (homepage on internet).c2015.(updated 31 Mar 2015, cited 30 Nov 2015). Available at www.who.int/tb/publications/global_report/gtbr14_executive_summary.pdf (last Assessed on 25 Mar 2017).
  16. Carvalho B, Monteiro A, Neto R, et al. Factors related to HIV/tuberculosis co-infection in a Brazilian reference hospital. Braz J Infect Dis 2008;12(4):281–286. DOI: 10.1590/s1413-86702008000400005.
  17. Rajasekaran S, Mahilmaran A, Annadurai S, et al. Manifestation of tuberculosis in patients with human immunodeficiency virus, Chennai, India. Annals of Thoracic Medicine Journal 2006;2(2):58–60. DOI: 10.4103/1817-1737.32231.
  18. Shetty N, Shemko M, Vaz M, et al. An Epidemiological evaluation of risk factors for tuberculosis in South India. Int J Tuber Lung Dis 2006;10(1):80–86.
  19. Raizada N, Singh C, Khera A, et al. HIV Seroprevalence among tuberculosis patients in India, 2006–2007. PLoS ONE 2008;3(8):2970. DOI: 10.1371/journal.pone.0002970.
  20. Annual Report 2014-15. National AIDS Control Organization, Department of AIDS Control. Ministry of Health & Family Welfare, Government of India.
  21. Badri M, Wilson D, Wood R. Effect of highly active antiretroviral therapy on incidence of tuberculosis in South Africa: a cohort study. Lancet 2002;359(9323):2059–2064. DOI: 10.1016/S0140-6736(02)08904-3.
  22. Tran TM, Nguyen HT, Yatsuya H, et al. HIV prevalence and factors associated with HIV infection among male injection drug users under 30s: a cross sectional study in long an, Vietnam. BMC Public Health 2006;6(1):248. DOI: 10.1186/1471-2458-6-248.
  23. Yadav SP, Dixit AK. A study of the potential interventional variables associated with delay in diagnosis/treatment of pulmonary tuberculosis cases in the Thar desert of Rajasthan. DMRC Annual Report; 2005-06. pp. 39–44.
  24. Sonnenberg P, Glynn JR, Fielding K, et al. How soon after infection with HIV does the risk of tuberculosis start to increase? A retrospective cohort study in South African gold miners. J Infect Dis 2005;191(2):150–158. DOI: 10.1086/426827.
PDF Share

© Jaypee Brothers Medical Publishers (P) LTD.